STRO-004 Not publicly disclosed (no generic/INN name found in available sources) Updated Nov 13
The Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).
- Early Phase 1 data showed confirmed and ongoing unconfirmed partial responses in heavily pretreated patients with pancreatic, head and neck, and NSCLC cancers, suggesting clinical activity. (Source: Sutro Q2 2026 earnings press release, August 12, 2026)
- The drug uses a high DAR-8 exatecan payload with Sutro's site-specific conjugation technology, which preclinical data suggested may offer improved efficacy versus benchmark TF-targeting ADCs. (Source: AACR 2026 preclinical data presentation, April 2026)
- Analyst consensus is strongly bullish: 18 buy/strong-buy ratings, mean price target ~$47.23 vs current ~$9.73, implying roughly 390% upside.
- Dose-limiting toxicities were reported at the highest dose level in the Phase 1 study, raising questions about the therapeutic window. (Source: Benzinga summary of August 2026 STRO-004 update)
- The stock fell sharply after the August 2026 Phase 1 update, suggesting the market was not impressed by the early data. (Source: MSN/SeekingAlpha coverage, August 12, 2026)
- Tivdak (tisotumab vedotin) from Genmab is already approved for recurrent cervical cancer, establishing a competitive benchmark that STRO-004 must beat on efficacy or safety. (Source: Medscape/ASCO publications)